CHA 2 DS 2 VASc Score and Coronary No-Reflow Phenomenon

Abstract

Get full access to this article

View all access options for this article.

References

Kaya

Keskin

Tatlisu

, et al. Atrial fibrillation: a novel risk factor for no-reflow following primary percutaneous coronary intervention. Angiology. 2019;71(2):175–182. doi: 10.1177/0003319719840589

Kim

Hwang

, et al. Other Korean working group in myocardial infarction registry investigators. The CHA₂DS₂VASc score can be used to stratify the prognosis of acute myocardial infarction patients irrespective of presence of atrial fibrillation. J Cardiol. 2015;65:121–7.

Kılıc

Kocabas

Can

Yavuzgil

Çetin

Zoghi

. Predictive value of CHA₂DS₂VASc and CHA₂DS₂VASc -HS scores for failed reperfusion after thrombolytic therapy in patients with ST-elevation myocardial infarction. Cardiol J. 2018;26(2):169–175.

Tanık

Aruğaslan

Çinar

Keskin

Kaya

Tekkeşin

. Association of the CHA₂DS₂VASc score with acute stent thrombosis in patients with an ST elevation myocardial infarction who underwent a primary percutaneous coronary intervention. Med Princ Pract. 2018;28(2):115–123.

Durante

Camici

. Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol. 2015;187:273–80.

Di Carli

Janisse

Ager

Grunberger

. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41(8):1387–93.

Opherk

Mall

Zebe

, et al. Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation. 1984;69(1):1–7.